Nuvation Bio Inc. Class A Common Stock (NUVB)

The bulls are lining up on Wall Street for this up-and-coming biotech stock.

Nuvation Bio (NUVB) reported Q2 2025 results with a massive revenue beat ($4.83M vs. $364K est.) driven by IBTROZI launch, but EPS met expectations (-$0.17). Cash at $607.7M, pipeline progressing.

FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing high response rates.

Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage pipeline developments.

NUVB stock results show that Nuvation Bio beat analyst estimates for earnings per share the first quarter of 2024.

Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a foreign company in the last four months By Doug Young

U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday.

South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because of the competition for Alzheimer’s drugs.

Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates.